New flu vaccine with extra H3 strain shows promise in early trial
NCT ID NCT06507553
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed Phase 1 trial tested a new flu vaccine that includes an extra H3 strain, aiming to improve protection against influenza. The study involved 400 healthy adults aged 18-49 and 60+, comparing the new vaccine to standard flu shots. Researchers checked for side effects and measured immune responses over three weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Influenza vaccine with an extra H3 strain
What this could lead to
If successful, this could lead to a more effective flu vaccine that better protects against certain flu strains, especially for older adults.
What could go wrong
This is an early Phase 1 trial focused on safety and immune response, not yet proven to prevent flu. The extra strain may not improve protection and could cause more side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number : 0360001
Melbourne, Victoria, 3124, Australia
-
Investigational Site Number : 0360002
Botany, New South Wales, 2019, Australia
-
Investigational Site Number : 0360003
Southport, Queensland, 4222, Australia
-
Investigational Site Number : 0360004
Sippy Downs, Queensland, 4556, Australia
-
Investigational Site Number : 0360005
Morayfield, 4506, Australia
-
Investigational Site Number : 0360007
Adelaide, South Australia, 5067, Australia
-
Investigational Site Number : 0360010
Brookvale, New South Wales, 2100, Australia
-
Investigational Site Number : 0360011
Miranda, New South Wales, 2228, Australia
-
Investigational Site Number : 0360012
Maroubra, New South Wales, 2035, Australia
-
Investigational Site Number : 0360013
Taringa, Queensland, 4068, Australia